90% US cancer centers report cancer drug shortages, impacting patient treatment and clinical trials.

90% of US cancer centers report shortages of at least one cancer drug, affecting patient treatment and impeding new therapies progress, according to a recent National Comprehensive Cancer Network (NCCN) survey. The most impactful shortages are of vinblastine, etoposide, and topotecan. Cancer drug shortages have been a persistent problem, impacting clinical trials and treatment options for patients.